212 related articles for article (PubMed ID: 21172890)
1. Improved prognosis for older adolescents with acute lymphoblastic leukemia.
Pui CH; Pei D; Campana D; Bowman WP; Sandlund JT; Kaste SC; Ribeiro RC; Rubnitz JE; Coustan-Smith E; Jeha S; Cheng C; Metzger ML; Bhojwani D; Inaba H; Raimondi SC; Onciu M; Howard SC; Leung W; Downing JR; Evans WE; Relling MV
J Clin Oncol; 2011 Feb; 29(4):386-91. PubMed ID: 21172890
[TBL] [Abstract][Full Text] [Related]
2. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Wang Y; Zeng HM; Zhang LP
Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
[TBL] [Abstract][Full Text] [Related]
3. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
4. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
5. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
6. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
7. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
8. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.
Bhojwani D; Pei D; Sandlund JT; Jeha S; Ribeiro RC; Rubnitz JE; Raimondi SC; Shurtleff S; Onciu M; Cheng C; Coustan-Smith E; Bowman WP; Howard SC; Metzger ML; Inaba H; Leung W; Evans WE; Campana D; Relling MV; Pui CH
Leukemia; 2012 Feb; 26(2):265-70. PubMed ID: 21869842
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
10. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
[TBL] [Abstract][Full Text] [Related]
11. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
13. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Biondi A; Schrappe M; De Lorenzo P; Castor A; Lucchini G; Gandemer V; Pieters R; Stary J; Escherich G; Campbell M; Li CK; Vora A; Aricò M; Röttgers S; Saha V; Valsecchi MG
Lancet Oncol; 2012 Sep; 13(9):936-45. PubMed ID: 22898679
[TBL] [Abstract][Full Text] [Related]
14. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol.
Gandemer V; Chevret S; Petit A; Vermylen C; Leblanc T; Michel G; Schmitt C; Lejars O; Schneider P; Demeocq F; Bader-Meunier B; Bernaudin F; Perel Y; Auclerc MF; Cayuela JM; Leverger G; Baruchel A;
Haematologica; 2012 Nov; 97(11):1743-50. PubMed ID: 22580999
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after induction failure in childhood acute lymphoblastic leukemia.
Schrappe M; Hunger SP; Pui CH; Saha V; Gaynon PS; Baruchel A; Conter V; Otten J; Ohara A; Versluys AB; Escherich G; Heyman M; Silverman LB; Horibe K; Mann G; Camitta BM; Harbott J; Riehm H; Richards S; Devidas M; Zimmermann M
N Engl J Med; 2012 Apr; 366(15):1371-81. PubMed ID: 22494120
[TBL] [Abstract][Full Text] [Related]
16. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
17. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
[TBL] [Abstract][Full Text] [Related]
18. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Schrappe M; Bleckmann K; Zimmermann M; Biondi A; Möricke A; Locatelli F; Cario G; Rizzari C; Attarbaschi A; Valsecchi MG; Bartram CR; Barisone E; Niggli F; Niemeyer C; Testi AM; Mann G; Ziino O; Schäfer B; Panzer-Grümayer R; Beier R; Parasole R; Göhring G; Ludwig WD; Casale F; Schlegel PG; Basso G; Conter V
J Clin Oncol; 2018 Jan; 36(3):244-253. PubMed ID: 29148893
[TBL] [Abstract][Full Text] [Related]
19. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
